Drug Search Results

Orvepitant

Alternative Names: orvepitant, gw-823296, gw823296, gw 823296
Latest Update: 2024-06-24
Latest Update Note: Clinical Trial Update

Product Description

Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Nerre
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Orvepitant

Countries in Clinic: Netherlands, United Kingdom, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Chronic Cough|Idiopathic Pulmonary Fibrosis

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
IPF-COMFORT	P2	Completed	Chronic Cough\|Idiopathic Pulmonary Fibrosis	2024-06-05	35%
2021-006278-22	P2	Active, not recruiting	Idiopathic Pulmonary Fibrosis\|Chronic Cough	2024-03-29

Recent News Events

Date	Type	Title
05/25/2023	News Article	Idiopathic Pulmonary Fibrosis Market to Surpass US$ 7,521.2 Million by 2030, Says Coherent Market Insights (CMI)
09/01/2022	PubMed	Managed care considerations for the treatment of chronic cough.
07/19/2021	News Article	Chronic Refractory Cough Market Size To Experience Subsequent Growth at a CAGR of 6.57% During the Study Period 2018-2030
07/12/2021	News Article	Osborne Clarke advises NeRRe Therapeutics on its £20 million Series B2 financing round
07/07/2021	News Article	NeRRe Therapeutics raises £20 million in a Series B2 financing round
02/06/2020	PubMed	Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.
01/01/2020	PubMed	The Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough: Results From a Phase 2 Pilot Study (VOLCANO-1).

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions